The role of (auto)-phosphorylation in the complex activation mechanism of LRRK2 by Athanasopoulos, Panagiotis S et al.
  
 University of Groningen
The role of (auto)-phosphorylation in the complex activation mechanism of LRRK2





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Athanasopoulos, P. S., Heumann, R., & Kortholt, A. (2018). The role of (auto)-phosphorylation in the
complex activation mechanism of LRRK2. Biological Chemistry, 399(7), 643-647.
https://doi.org/10.1515/hsz-2017-0332
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Biol. Chem. 2018; 399(7): 643–647
Minireview
Panagiotis S. Athanasopoulos, Rolf Heumann and Arjan Kortholt*
The role of (auto)-phosphorylation in the complex 
activation mechanism of LRRK2
https://doi.org/10.1515/hsz-2017-0332
Received December 27, 2017; accepted February 6, 2018;  previously 
published online February 14, 2018
Abstract: Mutations in human leucine-rich-repeat kinase 
2 (LRRK2) have been found to be the most frequent cause 
of late-onset Parkinson’s Disease (PD). LRRK2 is a large 
protein with two enzymatic domains, a GTPase and a 
kinase domain. A cluster of (auto)-phosphorylation sites 
within the N-terminus of LRRK2  have been shown to be 
crucial for the localization of LRRK2 and is important for 
PD pathogenesis. In addition, phosphorylation of sites 
within the G-domain of the protein affect GTPase activity. 
Here we discuss the role of these (auto)-phosphorylation 
sites of LRRK2 and their regulation by phosphatases and 
upstream kinases.
Keywords: GTPase; kinase; neuronal degeneration; Par-
kinson’s disease; phosphatases.
Introduction
Human leucine-rich-repeat kinase 2 (LRRK2) has been 
identified to be the leading cause of late-onset heredi-
tary Parkinson’s disease (PD) (Gasser et  al., 2011). PD is 
a common neurodegenerative disorder affecting 1–2% of 
the Western world’s population (reviewed in Lees et  al., 
2009) and is characterized by the progressive death of 
dopaminergic neurons in the midbrain associated with 
the formation of fibrillar aggregates that consist mainly 
of α-synuclein and other proteins. LRRK2 mutations ini-
tiate an age dependent phenotype with complete clinical 
and neurochemical overlap with idiopathic disease (Healy 
et al., 2008; Alcalay et al., 2013). However, the penetrance 
of the LRRK2 mutations is even incomplete at later age and 
might partly depend on additional genes or environmental 
factors (Trinh et al., 2014). Mutations within LRRK2 have 
been identified in 5–6% of patients with familiar PD, 
but importantly have also been found in patients with 
sporadic PD (Lesage et al., 2007), while some LRRK2 PD 
patients can demonstrate quite a pleomorphic pathology 
(Zimprich et al., 2004). Despite a vast amount of research 
and the identification of several LRRK2  mediated path-
ways and interaction partners, the complete role of LRRK2 
in the cell, and how different mutations of LRRK2 are con-
tributing to the progression of the disease is still not well 
understood (Cookson and Bandmann, 2010). Importantly, 
LRRK2 interacts with synaptic vesicle proteins including 
synaptojanin-1 and Rab proteins were recently identified 
as the first physiological substrates of LRRK2, suggesting 
a role for LRRK2 in vesicle trafficking (Islam et al., 2016; 
Steger et al., 2016; Carrion et al., 2017; Pan et al., 2017).
LRRK2 is a large protein with two enzymatic domains, 
a GTPase and a kinase domain, and in addition several pro-
tein-protein interaction domains (Figure 1). Most of the PD 
mutations are located within the enzymatic core. Although 
it is generally accepted that the kinase activity of LRRK2 is 
essential for PD-mediated neuronal toxicity, conflicting 
data for the effect of the various PD mutations on LRRK2 
kinase activity have been reported (reviewed by Greggio 
and Cookson, 2009). The main reason for these conflict-
ing data was the lack of a physiological substrate. Data of 
recent studies that measured the phosphorylation of Rab 
proteins, the physiological LRRK2  substrates, strongly 
suggest that all common PD-mutations result in increased 
kinase activity (Steger et al., 2016). Interestingly, several 
of these mutations not only result in increased kinase 
activity, but also decreased GTPase activity (reviewed in 
(Terheyden et al., 2016), suggesting cross talk between the 
two enzymatic domains. Recent data suggest that LRRK2 
kinase activity is regulated by the Roc domain, but that 
vice versa the kinase domain also regulates LRRK2 GTPase 
activity via auto-phosphorylation of the Roc domain 
(Figure  2) (reviewed in Terheyden  et  al.,  2016). Other 
*Corresponding author: Arjan Kortholt, Department of Cell 
Biochemistry, University of Groningen, Nijenborgh 7, NL-9747 AG 
Groningen, The Netherlands, e-mail: a.kortholt@rug.nl
Panagiotis S. Athanasopoulos: Department of Cell Biochemistry, 
University of Groningen, Nijenborgh 7, NL-9747 AG Groningen, The 
Netherlands; and Faculty of Chemistry and Biochemistry, Molecular 
Neurobiochemistry, Ruhr University Bochum, Universitätstrasse 150, 
D-44780 Bochum, Germany
Rolf Heumann: Faculty of Chemistry and Biochemistry, Molecular 
Neurobiochemistry, Ruhr University Bochum, Universitätstrasse 150, 
D-44780 Bochum, Germany
Brought to you by | University of Groningen
Authenticated
Download Date | 6/20/18 11:56 AM
644      P.S. Athanasopoulos et al.: LRRK2 auto-phosphorylation
(auto)-phosphorylation sites, within the  N-terminus of 
LRRK2, are important for proper localization and binding 
to upstream and downstream regulators (Dzamko et  al., 
2010; Nichols et al., 2010; Doggett et al., 2012; Lobbestael 
et al., 2013). Here we highlight the important role of these 
LRRK2 (auto)-phosphorylation and discuss their regula-
tion by upstream kinases and phosphatases.
Function and  regulation 
of LRRK2 N-terminus 
phosphorylation
Phosphorylation of a cluster of serines (S910, S935, S955 
and S973) within the N-terminal part of LRRK2 (West 
et  al., 2007) has been shown to be essential for interac-
tion with 14-3-3 (Dzamko et al., 2010; Nichols et al., 2010; 
Doggett et al., 2012; Lobbestael et al., 2013). Disruption of 
S935 phosphorylation results in impaired 14-3-3 binding 
and subsequently to the delocalization of LRRK2 protein 
to microtubules, instead of being transported from the 
cytosol to membranes (Nichols et al., 2010; Ramírez et al., 
2017) (Figure 2). As addition of LRRK2 kinase inhibitors 
also resulted in the disruption of the 14-3-3/LRRK2 inter-
action, several studies postulated that these sites are pri-
marily regulated by auto-phosphorylation (Dzamko et al., 
2010; Nichols et  al., 2010; Doggett et  al., 2012; Lobbes-
tael et al., 2013). However, it is now clear that PKA is the 
major regulator of S935 phosphorylation (West et al., 2007; 
Doggett et  al., 2012). Dephosphorylation of S910/S935/
S955 and S973 is facilitated by protein phosphatase 1 (PP1) 
and thereby stimulates the dissociation of 14-3-3 protein 
from LRRK2 (Lobbestael et al., 2013) (Figure 2). LRRK2 PD 
mutants showed enhanced PP1 binding compared to wild-
type LRRK2 (Lobbestael et  al., 2013) and consequently 
reduced S910 and S935 phosphorylation and reduced 
14-3-3 binding (Nichols et al., 2010; Doggett et al., 2012). 
Consistently, increased 14-3-3 binding to LRRK2 seems to 






























Figure 2: Regulation and function of N-terminal LRRK2 (auto)-phosphorylation sites.
Phosphorylation of S910, S935, S955 and S973 is induced by both auto-phosphorylation and upstream kinases such as PKA (S935). In addi-
tion, PKA is able to phosphorylate S1444 within the Roc domain. PP1 dephosphorylates the N-terminal sites. 14-3-3 binds in a phosphoryla-
tion dependent way to the N-terminal serine cluster and thereby regulates its localization.








Figure 1: Schematic representation of LRRK2.
The domains of LRRK2 are shown with different colors. Below the most common PD associated mutations are indicated.
Brought to you by | University of Groningen
Authenticated
Download Date | 6/20/18 11:56 AM
P.S. Athanasopoulos et al.: LRRK2 auto-phosphorylation      645
length of G2019S neuronal cultures (Lavalley et al., 2016). 
These results show that N-terminal LRRK2 phosphoryla-
tion is important for PD pathogenesis and that it is thus 
important to further investigate the PP1/LRRK2 interaction 
and completely characterize the pathways and signals 
that regulate N-terminal LRRK2 phosphorylation.
Function and regulation of Roc 
phosphorylation
Also within the Roc domain a 14-3-3 binding site has been 
identified (Muda et al., 2014). PKA mediated phosphoryla-
tion of LRRK2 S1444 stimulates binding to 14-3-3 (Figure 2). In 
addition, several potential auto-phosphorylation sites have 
been identified within the Roc domain, however, both the 
regulation and biological relevance of these sites remains 
largely unknown [reviewed in (Terheyden et  al., 2016)]. 
Conflicting results have been published about the impact of 
auto-phosphorylation of the Roc domain on LRRK2 GTPase 
activity. Taymans et  al. reported that auto-phosphoryla-
tion of the Roc domain results in increased GTP binding 
and GTPase activity (Taymans et  al., 2011). Consistently, 
Webber et  al. showed that upon auto-phosphorylation of 
the Roc domain, the GTP bound state is stabilized (Webber 
et al., 2011). However, in contrast it also has been reported 
that mutants with reduced kinase activity have increased 
GTPase activity (Greggio et al., 2009). Consistently mutants 
with increased kinase activity have normal GTP binding 
affinity, but reduced GTPase activity (West et  al., 2005; 
Greggio et al., 2006; Jaleel et al., 2007; Anand et al., 2009). 
Together this suggests that auto-phosphorylation of the 
Roc domain plays an important role in the regulation of the 
LRRK2 G-protein cycle, but that different phosphorylation 
sites might have a different impact on the GTPase activity. 
It is therefore crucial to better understand the kinetics and 
regulation of LRRK2 Roc phosphorylation.
So far it is unclear which phosphatases are regulating 
the phosphorylation state of the Roc domain. However, we 
recently identified protein phosphatase 2A (PP2A) as an 
interacting partner of the LRRK2 Roc domain (Athanaso-
poulos et al., 2016). PP2A interaction with LRRK2 is medi-
ated by the Roc domain and takes place in the perinuclear 
region of Hela cells. Although we could not identify the 
phosphorylation sites within LRRK2 yet, it is tempting to 
speculate that PP2A regulates dephosphorylation of sites 
within the Roc domain (Figure 3). Importantly, expression 
of PP2A partially protects SH-SY5Y cells expressing LRRK2 
R1441C and primary cortical neurons expressing LRRK2 
G2019S from LRRK2 PD-induced neurotoxicity. Consist-
ently, silencing the catalytic subunit of PP2A (PP2Ac) by 
shRNA in the same cell systems, resulted in increased 
mutant LRRK2-induced cell death. Thus, this shows that 
PP2A is important for the survival of cells expressing 
mutant forms of LRRK2. To explain the neuroprotective 
properties of PP2A’s enzymatic activity in LRRK2-induced 
parkinsonism, it will be crucial to identify the PP2A target 
sites and understand how the phosphorylation of these 
sites impacts GTPase and kinase activity.
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Figure 3: Intramolecular interplay between the LRRK2 Roc and kinase domain.
The Roc domain regulates the kinase domain, while the GTPase activity is regulated by the auto-phosphorylation of the Roc domain. T1404, 
T1410 and T1503 are some of the potential important auto-phosphorylation sites identified within the Roc domain.
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